RPO LLC’s Orchestra BioMed OBIO Stock Holding History

RPO LLC’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27,755	Closed	-$277K	–	159
2022 Q4	$277K	Buy	27,755 +3,554	+15%	+$35.3K	0.09%	110
2022 Q3	$240K	Buy	+24,201	New	+$240K	0.06%	148

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SFG

SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

RPO LLC's OBIO Position: Q1 2023 in Review

RPO LLC sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 27,755 shares — an estimated $277K sold.

RPO LLC first reported a position in OBIO in Q3 2022 and held it in 2 quarters. The position peaked at $277K in Q4 2022. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

RPO LLC reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
RPO LLC sold 27,755 Orchestra BioMed shares in Q1 2023, an estimated $277K.
RPO LLC first reported a position in Orchestra BioMed in Q3 2022 and held it in 2 quarters.
RPO LLC's Orchestra BioMed position peaked at $277K in Q4 2022.
22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on RPO LLC's 13F filing for Q1 2023, filed 11 May 2023.